Document Details

Generated Narrative: Bundle TEST PURPOSES ONLY - nimenrix

Document Subject

Generated Narrative: MedicinalProductDefinition mp61ed8c3f1f4d3021b93672950d48db1a

identifier: http://ema.europa.eu/identifier/EU/1/12/767/001

type: Medicinal Product

domain: Human use

status: active

legalStatusOfSupply: Medicinal product subject to medical prescription

name

productName: Nimenrix powder and solvent for solution for injection in pre-filled syringe

type: Full name

part

part: nan

type: Invented name part

part

part: nan

type: Scientific name part

part

part: nan

type: Strength part

part

part: nan

type: Pharmaceutical dose form part

Usages

-	Country	Jurisdiction	Language
*	EU	EU	en

Document Content

Generated Narrative: Composition composition-en-61ed8c3f1f4d3021b93672950d48db1a

identifier: http://ema.europa.eu/identifier/EU/1/12/767/001

status: Final

type: Package Leaflet

category: Raw

date: 2022-02-16 13:28:17+0000

author: Organization ACME industry

title: TEST PURPOSES ONLY - nimenrix

Attesters

What is in this leaflet

1. What Nimenrix is and what it is used for
2. What you need to know before you receive Nimenrix
3. How Nimenrix is given
4. Possible side effects
5. How to store Nimenrix
6. Contents of the pack and other information

What Nimenrix is and what it is used for Nimenrix is a vaccine which helps protect against infections caused by bacteria (germs) called Neisseria meningitidis" types A, C, W-135 and Y. Neisseria meningitidis" types A, C, W-135 and Y bacteria can cause serious illnesses such as: meningitis - an infection of the tissue that lines the brain and spinal cord. septicaemia - an infection of the blood. These infections are passed easily from person to person and can cause death if not treated. Nimenrix may be given to adults, adolescents, children and infants over the age of 6 weeks.

How Nimenrix works Nimenrix helps your body to produce its own protection (antibodies) against the bacteria. These antibodies help protect you against the diseases.

Nimenrix will only protect against infections caused by the bacteria Neisseria meningitidis types A, C, W-135 and Y.

Nimenrix should not be given if:

you are allergic to the active substances or any of the other ingredients in this vaccine (listed in section 6). Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue. See your doctor immediately if you notice any of these. If you are not sure, talk to your doctor or nurse before you receive Nimenrix.

Warnings and precautions: Check with your doctor or nurse before you receive this vaccine if:

you have an infection with a high temperature (over 38 C). If this applies to you, the vaccination will not be given until you are feeling better. A minor infection such as a cold should not be a problem. However, talk to your doctor or nurse first.

you have a bleeding problem or you bruise easily. If any of the above apply to you (or you are not sure), talk to your doctor or nurse before you receive Nimenrix.

Nimenrix may not fully protect everyone who is vaccinated. If you have a weak immune system (such as due to HIV infection or medicines that affect the immune system) you may not get a full benefit from Nimenrix.

Fainting can occur (mostly in adolescents) following, or even before, any needle injection. Therefore tell the doctor or nurse if you or your child fainted with a previous injection.

Other medicines and Nimenrix Tell your doctor or nurse if you are taking or have recently taken any other medicines, including other vaccines and medicines obtained without a prescription.

Nimenrix may not work as well if you are taking medicines that affect your immune system.

In infants, Nimenrix can be given concomitantly with combined diphtheria - tetanus - acellular pertussis (DTaP) vaccines, including combination DTaP vaccines with hepatitis B, inactivated poliovirus or Haemophilus influenzae type b (HBV, IPV or Hib) such as DTaP-HBV-IPV/Hib vaccine, and with 10-valent pneumococcal conjugate vaccine.

From age 1 year and above, Nimenrix can be given concomitantly with any of the following vaccines: hepatitis A (HAV) and hepatitis B (HBV) vaccines, measles - mumps - rubella (MMR) vaccine, measles - mumps - rubella - varicella (MMRV) vaccine, 10-valent pneumococcal conjugate vaccine or unadjuvanted seasonal influenza vaccine.

In the second year of life, Nimenrix can also be given concomitantly with combined diphtheria - tetanus - acellular pertussis (DTaP) vaccines, including combination DTaP vaccines with hepatitis B, inactivated poliovirus or Haemophilus influenzae type b (HBV, IPV or Hib) such as DTaP-HBV- IPV/Hib vaccine, and 13-valent pneumococcal conjugate vaccine.

In individuals aged 9 to 25 years, Nimenrix can be given concomitantly with human papillomavirus vaccine [Types 16, 18] and a combined diphtheria (reduced antigen content), tetanus and acellular pertussis vaccine.

Whenever possible, Nimenrix and a TT containing vaccine, such as DTaP-HBV-IPV/Hib vaccine, should be co-administered or Nimenrix should be administered at least one month before the TT containing vaccine.

A different injection site will be used for each vaccine.

Pregnancy and breast-feeding If you are pregnant, think you may be pregnant, plan to become pregnant or are breast-feeding, you must tell your doctor before receiving Nimenrix.

Driving and using machines Nimenrix is not likely to affect your ability to drive or use machines. However, do not drive or use any machines if you are feeling unwell. Nimenrix contains sodium This vaccine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium-free .

Nimenrix will be given to you by a doctor or nurse. Nimenrix is always injected into a muscle, usually in the upper arm or thigh.

Primary immunisation

Infants from 6 weeks to less than 6 months of age
Two injections given 2 months apart at e.g. 2 and 4 months of age (the first injection may be given from the age of 6 weeks).

Infants from 6 months of age, children, adolescents and adults One injection.

Booster doses

Infants from 6 weeks to less than 12 months of age:
One booster dose at 12 months of age, at least 2 months after the last dose of Nimenrix.

Previously vaccinated individuals 12 months of age and older:
Please tell your doctor if you have received a previous injection with another meningococcal vaccine than Nimenrix. Your doctor will tell you if and when you need an additional dose of Nimenrix, especially if you or your child:

received your first dose at age 6-14 months and could be at particular risk of infection caused by Neisseria meningitidis types W-135 and Y

received your dose more than approximately one year ago and could be at risk of infection caused by Neisseria meningitidis type A

received your first dose at age 12-23 months and could be at particular risk of infection caused by Neisseria meningitidis types A, C, W-135 and Y

You will be informed when you or your child should come back for the next injection. If you or your child misses a scheduled injection, it is important that you make another appointment.

Make sure you or your child finishes the complete vaccination course.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:

Very common (these may occur with more than 1 in 10 doses of the vaccine):

fever

tiredness (fatigue)

headache

feeling drowsy

loss of appetite

feeling irritable

swelling, pain and redness where the injection is given.

Common (these may occur with up to 1 in 10 doses of the vaccine):

bruising (haematoma) where the injection is given

stomach and digestion problems such as diarrhoea, vomiting and nausea

rash (infants).

Uncommon (these may occur with up to 1 in 100 doses of the vaccine):

rash

hives

itching

crying

feeling dizzy

aching muscles

pain in the arms or legs

generally feeling unwell

difficulty sleeping

decreased feeling or sensitivity, especially in the skin

reactions where the injection is given such as itching, a feeling of warmth or numbness or a hard lump.

Rare (these may occur up to 1 in 1,000 doses of the vaccine):

fits (seizures) associated with a high temperature

Not known: frequency cannot be estimated from the available data

injection site swelling and redness; this may affect a large area of the vaccinated limb

enlarged lymph nodes

Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.

Store in a refrigerator (2 C - 8 C).

Store in the original package in order to protect from light.

Do not freeze.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

What Nimenrix contains

The active substances are:

After reconstitution, 1 dose (0.5 ml) contains:

Neisseria meningitidis group A polysaccharide1 5 micrograms

Neisseria meningitidis group C polysaccharide1 5 micrograms

Neisseria meningitidis group W-135 polysaccharide1 5 micrograms

Neisseria meningitidis group Y polysaccharide1 5 micrograms

1conjugated to tetanus toxoid carrier protein 44 micrograms

The other ingredients are:

In the powder: sucrose and trometamol

In the solvent: sodium chloride (see section 2 Nimenrix contains sodium ) and water for injections

What Nimenrix looks like and contents of the pack Nimenrix is a powder and a solvent for solution for injection. Nimenrix is supplied as a white powder or cake in a single dose glass vial and a clear and colourless solvent in a pre-filled syringe. These must be mixed together before use. The mixed vaccine will appear as a clear colourless solution. Nimenrix is available in packs of 1 or 10 with or without needles.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder:
Pfizer Europe MA EEIG Boulevard de la Plaine 1050 Bruxelles Belgium

Manufacturer responsible for batch release: Pfizer Manufacturing Belgium N.V. Rijksweg B-2870 Puurs
Belgium

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Belgi /Belgique/Belgien Luxembourg/Luxemburg Pfizer S.A./N.V. T l/Tel: + 32 (0)2 554 62 Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel. + 370 52 51 4
,
Te : +359 2 970 4Magyarorsz g Pfizer Kft Tel: +36 1 488 3 esk Republika Pfizer, spol. s r.o. Tel: +420 283 004 Malta Vivian Corporation Ltd. Tel: + 35621 344Danmark Pfizer ApS Tlf: + 45 44 201 Nederland Pfizer BV Tel: +31 (0)800 63 34 Deutschland Pfizer Pharma GmbH Tel: + 49 (0)30 550055-51Norge Pfizer AS Tlf: +47 67 526 Eesti Pfizer Luxembourg SARL Eesti filiaal Tel.: +372 666 7 sterreich Pfizer Corporation Austria Ges.m.b.H Tel: + 43 (0)1 521 15-0

Pfizer A.E. .: +30 210 6785 Polska Pfizer Polska Sp. z o.o. Tel.: +48 22 335 61 Espa a Pfizer, S.L. T lf: +34914909Portugal Laborat rios Pfizer, Lda. Tel: +351 21 423 5France Pfizer T l +33 1 58 07 34 Rom nia Pfizer Romania S.R.L Tel: +40 (0) 21 207 28 Hrvatska
Pfizer Croatia d.o.o. Tel: + 385 1 3908 Slovenija Pfizer Luxembourg SARL Pfizer, podru nica za svetovanje s podro ja farmacevtske dejavnosti, Ljubljana Tel.: + 386 (0) 1 52 11 Ireland Pfizer Healthcare Ireland Tel: 1800 633 363 (toll free) +44 (0)1304 616Slovensk republika Pfizer Luxembourg SARL, organiza n zlo ka Tel: + 421 2 3355 5 sland Icepharma hf Simi: + 354 540 8Suomi/Finland Pfizer Oy Puh/Tel: +358 (0)9 430 Italia Pfizer S.r.l.
Tel: +39 06 33 18 Sverige Pfizer AB Tel: +46 (0)8 550 520 K
Pfizer . . (Cyprus Branch)
T : +357 22 817United Kingdom (Northern Ireland) Pfizer Limited
Tel: +44 (0) 1304 616Latvija Pfizer Luxembourg SARL fili le Latvij
Tel.: + 371 670 35 This leaflet was last revised in {MM/YYYY}

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: